Waverley Pharma Inc. (FRA:5GZ)

Germany flag Germany · Delayed Price · Currency is EUR
0.0060
0.00 (0.00%)
Last updated: Nov 28, 2025, 9:59 AM CET
-33.33%
Market Cap497.75K
Revenue (ttm)921.24K
Net Income (ttm)-224.63K
Shares Outn/a
EPS (ttm)-0.00
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volumen/a
Open0.0060
Previous Close0.0060
Day's Range0.0060 - 0.0060
52-Week Range0.0040 - 0.0140
Betan/a
RSI22.44
Earnings DateNov 27, 2025

About Waverley Pharma

Waverley Pharma Inc., a biopharmaceutical company, researches, develops, and commercializes oncology therapeutics in the United Kingdom. The company develops poly ADP-ribose polymerase-1 (PARP-1) inhibitors for cancer treatment. It also operates a retail pharmacy in the United States. Waverley Pharma Inc. was founded in 2014 and is headquartered in Winnipeg, Canada. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2014
Country Canada
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 5GZ
Full Company Profile

Financial Performance

In 2024, Waverley Pharma's revenue was 475,373, an increase of 15.36% compared to the previous year's 412,090. Losses were -947,077, -57.42% less than in 2023.

Financial numbers in CAD Financial Statements

News

There is no news available yet.